The current project will assemble a library of molecules known as single-chain variable fragment (scFv) antibodies to treat COVID-19. The scFv antibodies will neutralize the SARV-CoV-2 coronavirus that causes COVID-19 by targeting its spike (S) glycoprotein. ScFv antibodies offer numerous advantages compared to other treatment alternatives such as small-molecule drugs and monoclonal antibodies, and are […]
Read More